Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity extension of bivalent HPV vaccine (Walrinvax) in women aged 9–26 years
CTR20230424Phase 4Active
- Sponsor
- Yuxi Zerun Biotechnology Co., Ltd.
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus 16/18 bivalent vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), human papillomavirus infection, sponsored by Yuxi Zerun Biotechnology Co., Ltd.. Started Mar 2023; status: active.
02
Drugs
human papillomavirus 16/18 bivalent vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)human papillomavirus infection
Beyond the preview
Go deeper on CTR20230424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230424.